Gastrointestinal cancers
5 trials- 2021CheckMate-577Oesophageal adjuvantIn 794 patients with resected oesophageal/GEJ cancer and residual pathologic disease after neoadjuvant chemoradiation, adjuvant nivolumab for one year improved disease-free survival compared with placebo.
- 2020KEYNOTE-177MSI-H mCRCIn 307 patients with untreated MSI-H/dMMR metastatic colorectal cancer, pembrolizumab improved progression-free survival compared with chemotherapy ± targeted agents.
- 2011PRODIGE 4 / ACCORD 11Metastatic pancreaticIn 342 patients with metastatic pancreatic adenocarcinoma, ECOG 0–1, age ≤75, FOLFIRINOX improved overall survival compared with gemcitabine.
- 2009CRYSTALmCRC anti-EGFRIn 1,198 patients with untreated metastatic colorectal cancer, cetuximab + FOLFIRI improved PFS in the KRAS/RAS wild-type subgroup compared with FOLFIRI alone.
- 2004MOSAICColon adjuvantIn 2,246 patients with resected stage II/III colon cancer, adjuvant FOLFOX4 improved disease-free survival compared with 5-FU/leucovorin.